Literature DB >> 22266731

High-sodium intake aggravates myocardial injuries induced by aldosterone via oxidative stress in Sprague-Dawley rats.

Jing-yi Li1, Shao-ling Zhang, Meng Ren, Yan-ling Wen, Li Yan, Hua Cheng.   

Abstract

AIM: To evaluate the effects of aldosterone with or without high sodium intake on blood pressure, myocardial structure and left ventricular function in rats, and to investigate the mechanisms underlying the effects.
METHODS: Eight-week-old male Sprague-Dawley rats were randomly divided into 3 groups: (1) control (CON) group fed a normal sodium diet, (2) aldosterone (ALD) group receiving aldosterone infusion and a normal sodium diet, and (3) high sodium plus aldosterone (HS-ALD) group receiving 1% NaCl diet in conjunction with aldosterone infusion. Aldosterone was administered through continuously subcutaneous infusion with osmotic minipump at the rate of 0.75 μg/h for 8 weeks. The myocardium structure was observed using transthoracic echocardiography and transmission electron microscopy. The collagen deposition in left ventricle was evaluated with Masson's trichrome staining. The expression of IL-18, p22phox, and p47phox proteins was examined using Western blot analysis.
RESULTS: The systolic blood pressure in the ALD and HS-ALD groups was significantly higher than that in the CON group after 2-week treatment. But the blood pressure showed no significant difference between the HS-ALD and ALD groups. The left ventricular hypertrophy, myocardial collagen deposition and oxidative stress were predominantly found in the HS-ALD and ALD group. Furthermore, the breakdown of myocardial structure and oxidative stress were more apparent in the HS-ALD group as compared with those in the ALD group.
CONCLUSION: Long-term infusion of aldosterone results in hypertension and profibrotic cardiovascular responses in rats fed a normal sodium diet, which were mediated by oxidative stress. High-sodium intake could aggravate myocardial injuries induced by aldosterone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266731      PMCID: PMC4077133          DOI: 10.1038/aps.2011.179

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  31 in total

1.  Aldosterone-induced inflammation in the rat heart : role of oxidative stress.

Authors:  Yao Sun; Jiakun Zhang; Li Lu; Sue S Chen; Mark T Quinn; Karl T Weber
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  TNF-alpha and H2O2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation.

Authors:  Bysani Chandrasekar; James T Colston; Sam D de la Rosa; Perla P Rao; Gregory L Freeman
Journal:  Biochem Biophys Res Commun       Date:  2003-04-18       Impact factor: 3.575

3.  Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.

Authors:  Diego V Martinez; Ricardo Rocha; Mamiko Matsumura; Eveline Oestreicher; Margarita Ochoa-Maya; Weranuj Roubsanthisuk; Gordon H Williams; Gail K Adler
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Essential hypertension: renin and aldosterone, heart attack and stroke.

Authors:  H R Brunner; J H Laragh; L Baer; M A Newton; F T Goodwin; L R Krakoff; R H Bard; F R Bühler
Journal:  N Engl J Med       Date:  1972-03-02       Impact factor: 91.245

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

Review 6.  The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.

Authors:  Simon W Rabkin
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

7.  Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension.

Authors:  Lixin Li; Yi Chu; Gregory D Fink; John F Engelhardt; Donald D Heistad; Alex F Chen
Journal:  Hypertension       Date:  2003-09-29       Impact factor: 10.190

Review 8.  Aldosterone, mineralocorticoid receptors and vascular inflammation.

Authors:  John W Funder
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

9.  Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

Authors:  Ramachandran S Vasan; Jane C Evans; Martin G Larson; Peter W F Wilson; James B Meigs; Nader Rifai; Emelia J Benjamin; Daniel Levy
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

10.  NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats.

Authors:  Young Mee Park; Mi Young Park; Yeon-Lim Suh; Jeong Bae Park
Journal:  Biochem Biophys Res Commun       Date:  2004-01-16       Impact factor: 3.575

View more
  4 in total

1.  Steroidogenic acute regulatory protein/aldosterone synthase mediates angiotensin II-induced cardiac fibrosis and hypertrophy.

Authors:  Wei-Wei Zhang; Rong-Hua Zheng; Feng Bai; Katelyn Sturdivant; Ning-Ping Wang; Erskine A James; Himangshu S Bose; Zhi-Qing Zhao
Journal:  Mol Biol Rep       Date:  2019-12-09       Impact factor: 2.316

2.  Rotenone Attenuates Renal Injury in Aldosterone-Infused Rats by Inhibiting Oxidative Stress, Mitochondrial Dysfunction, and Inflammasome Activation.

Authors:  Wei Ding; Chengyan Xu; Bin Wang; Minmin Zhang
Journal:  Med Sci Monit       Date:  2015-10-17

3.  Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury.

Authors:  Wei Ding; Honglei Guo; Chengyan Xu; Bin Wang; Minmin Zhang; Feng Ding
Journal:  Oncotarget       Date:  2016-04-05

4.  Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism.

Authors:  Shao-Ling Zhang; Jing-Wei Gao; Ying Guo; Qi-Ling Feng; Ju-Ying Tang; Li Yan; Jing-Feng Wang; Hua Cheng; Pin-Ming Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-25       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.